-
Beibei Lu,
Raphael P Viscidi,
Yougui Wu,
Alan G Nyitray,
Luisa L Villa,
Eduardo Lazcano-Ponce,
Roberto J Carvalho da Silva,
Maria Luiza Baggio,
Manuel Quiterio,
Jorge Salmerón,
Danelle C Smith, Martha Abrahamsen,
Mary Papenfuss,
Anna R Giuliano
[show abstract]
[hide abstract]
ABSTRACT: It is largely unknown if antihuman papillomavirus (HPV) serum antibody responses vary by anatomic site of infection in men.
This study assessed type-specific anti-HPV serum antibody prevalence associated with corresponding HPV DNA detection in the external genitalia and the anal canal of 1,587 heterosexual men and 199 men who have sex with men (MSM).
We observed that HPV 6 and 16 seroprevalence was higher in the presence of same HPV-type infection in the anal canal compared with same HPV-type infection in the external genitalia only, and among MSM compared with the heterosexual men. Seropositivity to HPV 6 was strongly associated with HPV 6 DNA detection in the anal canal but not in the external genitalia alone among both heterosexual men [adjusted prevalence ratio (APR), anal+/genital+ vs. anal-/genital-: 4.2, 95% confidence interval (CI), 11.7-10.5; anal+/genital- vs. anal-/genital-: 7.9 (95% CI, 3.7-17.0)] and MSM [APR, anal+/genital+ vs. anal-/genital-: 5.6 (95% CI, 2.7-11.9); anal+/genital- vs. anal-/genital-: 3.2 (95% CI, 2.1-4.9)]. Similar associations between seropositivity to HPV 16 and anal HPV 16 DNA detection were only observed in MSM [anal+/genital+ vs. anal-/genital-: 3.1 (95% CI, 2.0-5.0); anal+/genital- vs. anal-/genital-: 2.2 (95% CI, 1.3-3.5)].
Our data showed that seroprevalence varied by anatomic site of HPV infection, suggesting differences in epithelium type present at these anatomic sites may be relevant. Impact: Our finding is instrumental in advancing our understanding of immune mechanism involved in anatomic site-specific antibody response. Cancer Epidemiol Biomarkers Prev; 21(9); 1542-6. ©2012 AACR.
Cancer Epidemiology Biomarkers & Prevention 07/2012; 21(9):1542-6. · 4.12 Impact Factor
-
Beibei Lu,
Raphael P Viscidi,
Yougui Wu,
Ji-Hyun Lee,
Alan G Nyitray,
Luisa L Villa,
Eduardo Lazcano-Ponce,
Roberto J Carvalho da Silva,
Maria Luiza Baggio,
Manuel Quiterio,
Jorge Salmeron,
Danelle C Smith, Martha E Abrahamsen,
Mary R Papenfuss,
Heather G Stockwell,
Anna R Giuliano
[show abstract]
[hide abstract]
ABSTRACT: In women, naturally induced anti-human papilloma virus (HPV) serum antibodies are a likely marker of host immune protection against subsequent HPV acquisition and progression to precancerous lesions and cancers. However, it is unclear whether the same is the case in men. In this study, we assessed the risk of incident genital infection and 6-month persistent genital infection with HPV16 in relation to baseline serostatus in a cohort of 2,187 men over a 48-month period. Genital swabs were collected every 6 months and tested for HPV presence. Incidence proportions by serostatus were calculated at each study visit to examine whether potential immune protection attenuated over time. Overall, incidence proportions did not differ statistically between baseline seropositive and seronegative men at any study visit or over the follow-up period. The risk of incident and 6-month persistent infection was not associated with baseline serostatus or baseline serum antibody levels in the cohort. Our findings suggest that baseline HPV seropositivity in men is not associated with reduced risk of subsequent HPV16 acquisition. Thus, prevalent serum antibodies induced by prior infection may not be a suitable marker for subsequent immune protection against genital HPV16 acquisition in men.
Cancer Research 11/2011; 72(3):676-85. · 7.86 Impact Factor
-
Beibei Lu,
Raphael P Viscidi,
Ji-Hyun Lee,
Yougui Wu,
Luisa L Villa,
Eduardo Lazcano-Ponce,
Roberto J Carvalho da Silva,
Maria Luiza Baggio,
Manuel Quiterio,
Jorge Salmerón,
Danelle C Smith, Martha Abrahamsen,
Mary Papenfuss,
Heather G Stockwell,
Anna R Giuliano
[show abstract]
[hide abstract]
ABSTRACT: Few human papillomavirus (HPV) serology studies have evaluated type-specific seroprevalence of vaccine HPV types in men. This study investigates seroprevalence of HPV 6, 11, 16, and 18, and associated risk factors in men residing in three countries (United States, Mexico, and Brazil).
Data from 1,477 men aged 18 to 70 enrolled in the HPV Infection in Men Study (HIM Study) were analyzed. Serum antibody testing was performed with virus-like particle-based ELISA. Potential risk factors were assessed for individual HPV types by the use of logistic regression.
Overall, HPV-6, 11, 16, and 18 seroprevalence was 14.8%, 17.3%, 11.2%, and 5.8%, respectively. Thirty-four percent of men were seropositive to one or more HPV types. When examined by sexual practice, 31.2% of men who had sex with women, 65.6% of men who had sex with men (MSM), and 59.4% of men who had sex with both men and women (MSMW) were seropositive to one or more HPV types. Seroprevalence increased with age among young-to-middle-aged men with significant upward age trends observed for HPV 11, 16, and 18. Men with multiple lifetime male anal sex partners were 2 to 4 times more likely to be HPV 6 or 11 seropositive and 3 to 11 times more likely to be HPV 16 or 18 seropositive.
Our data indicate that exposures to vaccine HPV types were common in men and highly prevalent among MSM and MSMW.
Our study provides strong evidence that the practice of same-sex anal intercourse is an independent risk factor for seroprevalence of individual vaccine HPV types. Examination of antibody responses to HPV infections at various anatomic sites in future studies is needed to elaborate on the mechanism.
Cancer Epidemiology Biomarkers & Prevention 03/2011; 20(5):990-1002. · 4.12 Impact Factor
